{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:05:05Z","timestamp":1793106305444,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hubei Province Health and Family Planning Scientific Research Project","award":["WJ2017Q006"],"award-info":[{"award-number":["WJ2017Q006"]}]},{"name":"Scientific Research Project of Hunan Health Commission","award":["202113010170 and 202213014496"],"award-info":[{"award-number":["202113010170 and 202213014496"]}]},{"name":"Project of Hunan Natural Science Foundation","award":["2023JJ50446"],"award-info":[{"award-number":["2023JJ50446"]}]},{"name":"Degree & Postgraduate Education Reform Project of Central South University","award":["2023JGB123"],"award-info":[{"award-number":["2023JGB123"]}],"id":[{"id":"https:\/\/ror.org\/00f1zfq44","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011930","name":"BEIJING Medical and health foundation","doi-asserted-by":"crossref","award":["YWJKJJHKYJJ-TYU139N"],"award-info":[{"award-number":["YWJKJJHKYJJ-TYU139N"]}],"id":[{"id":"10.13039\/501100011930","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      In this retrospective observational multicenter study, we aimed to assess efficacy and mortality between ceftazidime\/avibactam (CAZ\/AVI) or polymyxin B (PMB)-based regimens for the treatment of Carbapenem-resistant\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (CRKP) infections, as well as identify potential risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 276 CRKP-infected patients were enrolled in our study. Binary logistic and Cox regression analysis with a propensity score-matched (PSM) model were performed to identify risk factors for efficacy and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The patient cohort was divided into PMB-based regimen group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200998, 35.5%) and CAZ\/AVI-based regimen group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009178, 64.5%). Compared to the PMB group, the CAZ\/AVI group exhibited significantly higher rates of clinical efficacy (71.3% vs. 56.1%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), microbiological clearance (74.7% vs. 41.4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and a lower incidence of acute kidney injury (AKI) (13.5% vs. 33.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Binary logistic regression revealed that the treatment duration independently influenced both clinical efficacy and microbiological clearance. Vasoactive drugs, sepsis\/septic shock, APACHE II score, and treatment duration were identified as risk factors associated with 30-day all-cause mortality. The CAZ\/AVI-based regimen was an independent factor for good clinical efficacy, microbiological clearance, and lower AKI incidence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with CRKP infection, the CAZ\/AVI-based regimen was superior to the PMB-based regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-024-02324-8","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T03:01:46Z","timestamp":1718593306000},"page":"95-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study"],"prefix":"10.1007","volume":"53","author":[{"given":"Hai-Hui","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ming","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"2324_CR1","unstructured":"WHO. Global Priority list of antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. 348\u201365. WHO. 2017;348\u2013365."},{"key":"2324_CR2","doi-asserted-by":"publisher","unstructured":"Verdugo-Paiva F, Otaiza F, Roson-Rodriguez P, Rojas-Gomez AM, Galas M, El Omeiri N et al. Effects of screening strategies to detect carbapenem-resistant gram-negative bacteria: a systematic review. Am J Infect Control 2022https:\/\/doi.org\/10.1016\/j.ajic.2022.02.018","DOI":"10.1016\/j.ajic.2022.02.018"},{"issue":"7","key":"2324_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10096-020-03845-4","volume":"39","author":"O Perovic","year":"2020","unstructured":"Perovic O, Ismail H, Quan V, Bamford C, Nana T, Chibabhai V, et al. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clin Microbiol. 2020;39(7):1287\u201394. https:\/\/doi.org\/10.1007\/s10096-020-03845-4","journal-title":"Clin Microbiol"},{"key":"2324_CR4","doi-asserted-by":"publisher","first-page":"750662","DOI":"10.3389\/fmicb.2021.750662","volume":"12","author":"SL Chang","year":"2021","unstructured":"Chang SL, Dela Cruz CS, Zhang D, Clinical, Epidemiology. Risk factors, and control strategies of Klebsiella pneumoniae infection. Front Microbiol. 2021;12:750662. https:\/\/doi.org\/10.3389\/fmicb.2021.750662","journal-title":"Front Microbiol"},{"issue":"3","key":"2324_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s1473-3099(21)00399-6","volume":"22","author":"M Wang","year":"2022","unstructured":"Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2022;22(3):401\u201312. https:\/\/doi.org\/10.1016\/s1473-3099(21)00399-6","journal-title":"Lancet Infect Dis"},{"key":"2324_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/IDRS357746","volume":"15","author":"J Qu","year":"2022","unstructured":"Qu J, Qi TT, Qu Q, Long WM, Chen Y, Luo Y, et al. Polymyxin B-Based regimens for patients infected with carbapenem-resistant gram-negative Bacteria: clinical and microbiological efficacy, mortality, and Safety. Infect Drug Resist. 2022;15:1205\u201318. https:\/\/doi.org\/10.2147\/IDR.S357746","journal-title":"Infect Drug Resist"},{"key":"2324_CR7","doi-asserted-by":"publisher","first-page":"601968","DOI":"10.3389\/fcimb.2021.601968","volume":"11","author":"HY Chen","year":"2021","unstructured":"Chen HY, Jean SS, Lee YL, Lu MC, Ko WC, Liu PY, et al. Carbapenem-Resistant enterobacterales in Long-Term Care facilities: A Global and Narrative Review. Front Cell Infect Microbiol. 2021;11:601968. https:\/\/doi.org\/10.3389\/fcimb.2021.601968","journal-title":"Front Cell Infect Microbiol"},{"key":"2324_CR8","doi-asserted-by":"publisher","unstructured":"Stone GG, Newell P, Bradford PA. In Vitro Activity of Ceftazidime-Avibactam against isolates from patients in a phase 3 clinical trial for treatment of complicated intra-abdominal infections. Antimicrob Agents Chemother. 2018;62. https:\/\/doi.org\/10.1128\/AAC.02584-17","DOI":"10.1128\/AAC.02584-17"},{"issue":"Suppl 1","key":"2324_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","volume":"34","author":"M Matesanz","year":"2021","unstructured":"Matesanz M, Mensa J, Ceftazidime-avibactam. Rev Esp Quimioter. 2021;34(Suppl 1):38\u201340. https:\/\/doi.org\/10.37201\/req\/s01.11.2021","journal-title":"Rev Esp Quimioter"},{"key":"2324_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00682-0","author":"G Zheng","year":"2022","unstructured":"Zheng G, Cai J, Zhang L, Chen D, Wang L, Qiu Y, et al. Ceftazidime\/Avibactam-Based Versus Polymyxin B-Based therapeutic regimens for the treatment of Carbapenem-resistant Klebsiella pneumoniae infection in critically ill patients: a retrospective cohort study. Infect Dis Ther. 2022. https:\/\/doi.org\/10.1007\/s40121-022-00682-0","journal-title":"Infect Dis Ther"},{"key":"2324_CR11","doi-asserted-by":"publisher","first-page":"780940","DOI":"10.3389\/fphar.2021.780940","volume":"12","author":"J Fang","year":"2021","unstructured":"Fang J, Li H, Zhang M, Shi G, Liu M, Wang Y, et al. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk factors affecting clinical outcomes in patients with carbapenem-resistant Klebsiella pneumoniae infections a retrospective study. Front Pharmacol. 2021;12:780940. https:\/\/doi.org\/10.3389\/fphar.2021.780940","journal-title":"Front Pharmacol"},{"key":"2324_CR12","doi-asserted-by":"publisher","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-Avibactam is Superior to Other Treatment regimens against Carbapenem-resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8). https:\/\/doi.org\/10.1128\/AAC.00883-17","DOI":"10.1128\/AAC.00883-17"},{"key":"2324_CR13","volume-title":"Performance standards for Antimicrobial susceptibility testing","author":"C Institute","year":"2020","unstructured":"Institute C. Performance standards for Antimicrobial susceptibility testing. United States: CLSI; 2020."},{"issue":"9","key":"2324_CR14","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1093\/cid\/ciaa121","volume":"71","author":"MJ Satlin","year":"2020","unstructured":"Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial susceptibility testing position statements on Polymyxin B and Colistin Clinical breakpoints. Clin Infect Dis. 2020;71(9):e523. https:\/\/doi.org\/10.1093\/cid\/ciaa121","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2324_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00284-014-0552-5","volume":"69","author":"Y Yan","year":"2014","unstructured":"Yan Y, Yang H, Pan L, Sun K, Fan H, Lu Y, et al. Improving the efficiency of the modified Hodge test in KPC-producing Klebsiella pneumoniae isolates by incorporating an EDTA disk. Curr Microbiol. 2014;69(1):47\u201352. https:\/\/doi.org\/10.1007\/s00284-014-0552-5","journal-title":"Curr Microbiol"},{"issue":"12","key":"2324_CR16","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1128\/jcm01408-08","volume":"46","author":"Y Doi","year":"2008","unstructured":"Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J Clin Microbiol. 2008;46(12):4083\u20136. https:\/\/doi.org\/10.1128\/jcm.01408-08","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2324_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/14787210.2021.1935237","volume":"20","author":"I Karaiskos","year":"2022","unstructured":"Karaiskos I, Galani I, Papoutsaki V, Galani L, Giamarellou H. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev Anti Infect Ther. 2022;20(1):53\u201369. https:\/\/doi.org\/10.1080\/14787210.2021.1935237","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"2324_CR18","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the treatment of complicated intra-abdominal infection: results from a Randomized, controlled, Double-Blind, phase 3 program. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2016;62(11):1380\u20139. https:\/\/doi.org\/10.1093\/cid\/ciw133","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"3","key":"2324_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/s1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-Avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285\u201395. https:\/\/doi.org\/10.1016\/s1473-3099(17)30747-8","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2324_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin Versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2018;66(2):163\u201371. https:\/\/doi.org\/10.1093\/cid\/cix783","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"key":"2324_CR21","doi-asserted-by":"publisher","unstructured":"Almangour TA, Ghonem L, Aljabri A, Alruwaili A, Al Musawa M, Damfu N et al. Ceftazidime-Avibactam versus Colistin for the treatment of infections due to Carbapenem-Resistant enterobacterales: a Multicenter Cohort Study. Infection and drug resistance. 2022;15:211\u201321https:\/\/doi.org\/10.2147\/idr.S349004","DOI":"10.2147\/idr.S349004"},{"issue":"2","key":"2324_CR22","doi-asserted-by":"publisher","first-page":"e0260321","DOI":"10.1128\/spectrum.02603-21","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, Huang HB, Peng JM, Weng L, Du B. Efficacy and safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a systematic review and Meta-analysis. Microbiol Spectr. 2022;10(2):e0260321. https:\/\/doi.org\/10.1128\/spectrum.02603-21","journal-title":"Microbiol Spectr"},{"key":"2324_CR23","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.2147\/IDRS256922","volume":"13","author":"J Zhou","year":"2020","unstructured":"Zhou J, Yang J, Hu F, Gao K, Sun J, Yang J. Clinical and Molecular Epidemiologic Characteristics of Ceftazidime\/Avibactam-Resistant carbapenem-resistant Klebsiella pneumoniae in a neonatal intensive care unit in China. Infect Drug Resist. 2020;13:2571\u20138. https:\/\/doi.org\/10.2147\/IDR.S256922","journal-title":"Infect Drug Resist"},{"key":"2324_CR24","doi-asserted-by":"publisher","unstructured":"Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X et al. Emergence of ceftazidime\/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124 ehttps:\/\/doi.org\/10.1016\/j.cmi.2019.08.020","DOI":"10.1016\/j.cmi.2019.08.020"},{"key":"2324_CR25","doi-asserted-by":"publisher","unstructured":"Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X, et al. Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam. WIREs Mech Dis. 2022;e1571. https:\/\/doi.org\/10.1002\/wsbm.1571","DOI":"10.1002\/wsbm.1571"},{"key":"2324_CR26","doi-asserted-by":"publisher","unstructured":"Li X, Zhang J, Yang C, Li J, Wang J, Huang W, et al. Increased expression and amplification of blaKPC-2 contributes to resistance to Ceftazidime\/Avibactam in a sequence type 11 Carbapenem-resistant Klebsiella pneumoniae strain. Microbiol Spectr. 2022;e0095522. https:\/\/doi.org\/10.1128\/spectrum.00955-22","DOI":"10.1128\/spectrum.00955-22"},{"issue":"8","key":"2324_CR27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s11739-021-02749-1","volume":"16","author":"A Matlock","year":"2021","unstructured":"Matlock A, Garcia JA, Moussavi K, Long B, Liang SY. Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections. Intern Emerg Med. 2021;16(8):2231\u201341. https:\/\/doi.org\/10.1007\/s11739-021-02749-1","journal-title":"Intern Emerg Med"},{"issue":"3","key":"2324_CR28","doi-asserted-by":"publisher","first-page":"106536","DOI":"10.1016\/j.ijantimicag.2022.106536","volume":"59","author":"B Baland\u00edn","year":"2022","unstructured":"Baland\u00edn B, Ballesteros D, Pintado V, Soriano-Cuesta C, Cid-Tovar I, Sancho-Gonz\u00e1lez M, et al. Multicentre study of ceftazidime\/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59(3):106536. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106536","journal-title":"Int J Antimicrob Agents"},{"key":"2324_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jgar.2021.04.022","volume":"26","author":"J Gu","year":"2021","unstructured":"Gu J, Xu J, Zuo TT, Chen YB. Ceftazidime-Avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections. J Global Antimicrob Resist. 2021;26:20\u20135. https:\/\/doi.org\/10.1016\/j.jgar.2021.04.022","journal-title":"J Global Antimicrob Resist"},{"key":"2324_CR30","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.2147\/IDRS343505","volume":"14","author":"F Zhang","year":"2021","unstructured":"Zhang F, Zhong J, Ding H, Liao G. Efficacy of Ceftazidime-Avibactam in the treatment of Carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation. Infect Drug Resist. 2021;14:5165\u201374. https:\/\/doi.org\/10.2147\/IDR.S343505","journal-title":"Infect Drug Resist"},{"key":"2324_CR31","doi-asserted-by":"publisher","unstructured":"Zhou C, Jin L, Wang Q, Wang X, Chen F, Gao Y et al. Bloodstream infections caused by Carbapenem-Resistant Enterobacterales: risk factors for Mortality, Antimicrobial Therapy and Treatment outcomes from a prospective Multicenter Study. Infection and drug resistance. 2021;14:731\u201342https:\/\/doi.org\/10.2147\/idr.S294282","DOI":"10.2147\/idr.S294282"},{"issue":"7","key":"2324_CR32","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum \u03b2-lactamase Producing enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat Resistance (DTR-P. aeruginosa). Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;72(7):e169\u201383. https:\/\/doi.org\/10.1093\/cid\/ciaa1478","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"Suppl 2","key":"2324_CR33","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1093\/infdis\/jiaa247","volume":"222","author":"LM Busch","year":"2020","unstructured":"Busch LM, Kadri SS. Antimicrobial Treatment Duration in Sepsis and Serious infections. J Infect Dis. 2020;222(Suppl 2):S142\u201355. https:\/\/doi.org\/10.1093\/infdis\/jiaa247","journal-title":"J Infect Dis"},{"issue":"6","key":"2324_CR34","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/qco.0000000000000491","volume":"31","author":"JJ De Waele","year":"2018","unstructured":"De Waele JJ, Martin-Loeches I. Optimal duration of antibiotic treatment in Gram-negative infections. Curr Opin Infect Dis. 2018;31(6):606\u201311. https:\/\/doi.org\/10.1097\/qco.0000000000000491","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2324_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2018.11.008","volume":"94","author":"AF Oliota","year":"2019","unstructured":"Oliota AF, Penteado ST, Tonin FS, Fernandez-Llimos F, Sanches AC. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019;94(1):41\u20139. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"2324_CR36","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/jac\/dku561","volume":"70","author":"MH Rigatto","year":"2015","unstructured":"Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;70(5):1552\u20137. https:\/\/doi.org\/10.1093\/jac\/dku561","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2324_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for anti-infective pharmacology (ISAP), society of critical Care Medicine (SCCM), and Society of Infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339. https:\/\/doi.org\/10.1002\/phar.2209","journal-title":"Pharmacotherapy"},{"key":"2324_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijid.2022.01.055","volume":"117","author":"K Chang","year":"2022","unstructured":"Chang K, Wang H, Zhao J, Yang X, Wu B, Sun W, et al. Risk factors for polymyxin B-associated acute kidney injury. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2022;117:37\u201344. https:\/\/doi.org\/10.1016\/j.ijid.2022.01.055","journal-title":"Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis"},{"issue":"1","key":"2324_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40121-021-00556-x","volume":"11","author":"C Doremus","year":"2022","unstructured":"Doremus C, Marcella SW, Cai B, Echols RM. Utilization of Colistin Versus \u03b2-Lactam and \u03b2-Lactamase inhibitor agents in relation to acute kidney Injury in patients with severe gram-negative infections. Infect Dis Therapy. 2022;11(1):187\u201399. https:\/\/doi.org\/10.1007\/s40121-021-00556-x","journal-title":"Infect Dis Therapy"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02324-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T14:49:04Z","timestamp":1739458144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02324-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02324-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the ethical standards of the Helsinki Declaration (1964). The Ethics Committees of the Second Xiangya Hospital of Central South University approved it (LYF-2020021) and other ethics committees at each study site. Because of the study\u2019s retrospective and observational nature, it was exempted from the need for written informed consent. The Research Ethics Committee approved the study protocol and waived informed consent due to the retrospective nature of the study of each participating site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}